| |
While Clinical Pharmacology OnHand's
content is updated daily, we post
content and feature updates to this website for review
on a quarterly basis.
Content Updates
Version 2.28, November 2009
WHAT'S NEW:
None at this time.
|
NEW DRUG MONOGRAPHS INCLUDE:
- abobotulinumtoxinA (Dysport) – botulinum A toxin for cervical dystonia and glabellar lines in adults
- acetaminophen; diphenhydramine (Excedrin PM, Tylenol Cold Relief, and others) – combination analgesic and antihistamine for allergy symptoms or pain at bedtime
- adapalene; benzoyl peroxide (Epiduo) – combination retinoid and benzoyl peroxide product for acne vulgaris
- asenapine (Saphris) – new FDA-approval; atypical antipsychotic for acute schizophrenia and bipolar I disorder
- bacitracin; neomycin; polymyxin (Neosporin) – combination anti-infective for ocular infections and prevention of minor skin and skin structure infections
- bacitracin; polymyxin (Polysporin) – combination anti-infective for ocular infections and prevention of minor skin and skin structure infections
- dronedarone (Multaq) – new FDA-approval; antiarrhythmic for atrial fibrillation (AF) or atrial flutter (AFL); similar to amiodarone, but with possibly an improved safety profile
- ferumoxytol (Feraheme) – new FDA-approval; semi-synthetic, IV iron oxide for iron deficiency anemia in adults with chronic kidney disease
- iloperidone (Fanapt) – new FDA-approval; atypical antipsychotic for the acute treatment of schizophrenia
- morphine; naltrexone (Embeda) – new FDA approval; sustained release morphine for pain; sequestered with naltrexone to deter tampering
- pitavastatin (Livalo) – new FDA-approval; HMG-CoA reductase inhibitor for hypercholesterolemia and combined dyslipidemia
- polyethylene glycol; electrolytes; bisacodyl (HalfLytely and Bisacodyl Bowel Prep Kit) – combination bowel cleansing preparation; administered prior to colonoscopy
- prasugrel (Effient) – new FDA approval; thienopyridine platelet aggregation inhibitor for the reduction of thrombotic cardiovascular events in patients with ACS managed with PCI
- saxagliptin (Onglyza) – new FDA approval; oral dipeptidyl-peptidase-IV (DDP-IV) inhibitor for type 2 diabetes mellitus
- tapentadol (Nucynta) – synthetic mu-opioid receptor agonist and norepinephrine reuptake inhibitor for pain; similar in efficacy to morphine and oxycodone IR but with better GI tolerability
- tolvaptan (Samsca) – new FDA approval; oral V2 vasopressin receptor antagonist for hyponatremia in patients with heart failure, cirrhosis, or SIADH
- vigabatrin (Sabril) – new FDA-approval; antiepileptic drug; solution approved for infantile spasms in infants and children; tablets approved for refractory complex partial seizures in adults
UPDATED DRUG MONOGRAPHS INCLUDE:
- abatacept (Orencia) – monograph updated for FDA-approval for moderate to severe rheumatoid arthritis
- albuterol; ipratropium (Combivent, Duoneb) – monograph updated for post-marketing reports of myocardial ischemia
- aliskiren; hydrochlorothiazide, HCTZ (Tekturna HCT) – indications and dosage updated for initial use in patients likely to need multiple antihypertensive medications
- ambrisentan (Letairis) –ADRs updated for risk of decreased sperm counts
- anidulafungin (Eraxis) – administration updated for new formulation without dehydrated alcohol diluent
- atomoxetine (Strattera) – ADRs updated for hypoesthesia, lethargy, and in children, paresthesia, urinary retention, and hesitancy
- azelastine (Astepro) – monograph updated for FDA-approved higher concentration nasal spray for seasonal and perennial allergic rhinitis
- benzoyl peroxide (BenzEFoam) – indications and dosage updated for FDA-approved foam for mild or moderate acne vulgaris
- bevacizumab (Avastin) – monograph updated for new FDA approval for metastatic renal cell carcinoma and treatment recommendations in patients with proteinuria
- bosentan (Tracleer) – monograph updated for FDA-approval in pulmonary arterial hypertension (WHO Class I) with WHO Class II symptoms
- bupropion (Wellbutrin) – ADR section updated for QRS prolongation that has been reported in overdose situations
- bupropion (Zyban) – precautions updated for boxed warning for neuropsychiatric symptoms such as hostility, depressed mood, suicidal thoughts, and attempted suicide
- ceftriaxone (Rocephin) – ADRs updated for cephalosporin-induced hemolytic anemia
- colchicine (Colcrys) – monograph updated for first FDA-approved single ingredient formulation
- dexamethasone (Ozurdex) – monograph updated for new FDA-approved intravitreal implant for macular edema
- diclofenac (Cambia) – monograph updated to include 2 new FDA-approved formulations: an oral solution for migraine pain and a liquid capsule for pain
- eculizumab (Soliris) – monograph updated for risk of meningococcal infection; use is contraindicated in unresolved, serious Neisseria meningitidis infection and patients not currently vaccinated against Neisseria meningitidies
- fenofibric acid (Fibricor) – new FDA-approved tablet formulation for severe hypertriglyceridemia, primary hyperlipidemia, or mixed dyslipidemia
- fentanyl (Onsolis) – monograph updated for new FDA-approved transmucosal film for breakthrough pain in opioid tolerant patients
- gemcitabine (Gemzar) – indications and dosage updated for new trial results in pancreatic cancer
- glimepiride (Amaryl) – ADRs updated for allergic vasculitis
- haemophilus influenza type b conjugate vaccine (Hiberix) – new FDA approved formulation; a booster dose to be given after receipt of primary vaccination series
- human papilloma virus vaccine (Gardasil) – monograph updated for off-label use in women 27-45 years of age; ADRs updated for syncope, seizure-like activity, and falls
- hydrochlorothiazide, HCTZ; losartan (Hyzaar) – ADRs updated for rare occurrence of thrombocytopenia and post-marketing reports of general malaise
- hydrocortisone (Cortalo) – monograph updated for new FDA-approved gel for corticosteroid-responsive dermatoses
- ibritumomab (Zevalin) – monograph updated for FDA-approved indication for newly diagnosed follicular non-Hodgkin’s lymphoma
- insulin aspart (NovoLog) – administration updated for insulin pump recommendations including reservoir dwell times and frequency of infusion set and injection site changes
- interferon beta-1b (Extavia) – monograph updated for new FDA-approved formulation for relapsing-remitting multiple sclerosis
- ketorolac (Acuvail) – monographs updated for new FDA-approved ophthalmic formulation
- leuprolide (Lupron Depot) – monograph updated for post-marketing reports of seizures
- levocetirizine (Xyzal) – monograph updated for FDA-approval in children for idiopathic urticaria, perennial allergic rhinitis, and seasonal allergic rhinitis
- levonorgestrel (Plan B One-Step) – monograph updated for new 1.5 mg formulation with OTC approval in patients 17 years and older
- lisdexamfetamine (Vyvanse) – ADRs updated for post-marketing reports of blurred vision, mydriasis, diplopia, psychosis, mania, hallucinations, aggression, and logorrhea
- losartan (Cozaar) – ADRs updated for rare occurrence of thrombocytopenia and post-marketing reports of general malaise
- methylene blue – indications and dosage updated for off-label use in sentinel lymph node mapping and parathyroid gland localization
- olopatadine (Patanase) – ADRs and precautions updated for post-marketing reports of nasal perforation and probable drug-induced depression; FDA safety review ongoing
- onabotulinumtoxinA (Botox) – precautions updated for risk of systemic botulism
- orlistat (Xenical, Alli) – monograph updated for FDA early communication regarding possible liver injury
- oxaliplatin (Eloxatin) – indications and dosage updated for gastric cancer and new trial results in pancreatic cancer.
- paliperidone (Invega) – monograph updated for FDA-approval of oral formulation for schizoaffective disorder and extended-release injection for schizophrenia
- pancrelipase (Zenpep) – monograph updated for second FDA-approved formulation
- pemetrexed (Alimta) – indications and dosage updated for FDA-approved indication for advanced or metastatic non-small cell lung cancer
- poliovirus vaccine, inactivated, IPV (IPOL) – indications and dosing updated for revised ACIP recommendations for routine poliovirus vaccination
- rimabotulinumtoxinB (Myobloc) – precautions updated for risk of systemic botulism
- sevelamer (Renvela) – monograph updated for new FDA-approved powder for oral suspension
- sibutramine (Meridia) – monograph updated for reports of serotonin syndrome or neuroleptic malignant syndrome-like symptoms
- sorafenib (Nexavar) – indications and dosage updated with for renal cell carcinoma and recent study results for malignant melanoma
- sotalol – monograph updated for new FDA-approved intravenous formulation
- sumatriptan (Sumavel DosePro) – monograph updated for new FDA-approved single use, needle-free SC formulation for acute migraine and cluster headaches
- sunitinib (Sutent) – indications and dosage updated for recently study results for metastatic renal cell carcinoma
- tacrolimus (Prograf) – indications and dosage updated for liver and heart transplant rejection prophylaxis
- teriparatide (Forteo) – monograph updated for new FDA approval in glucocorticoid-induced osteoporosis and for rare post-market reports of osteosarcoma
- trastuzumab (Herceptin) – indications and dosage updated for recently reported study results in gastric cancer
- treprostinil (Tyvaso) – monograph updated for FDA-approved oral inhalation formulation for pulmonary arterial hypertension
- triamcinolone (Aristospan) – precautions updated for head trauma
- tumor necrosis factor (TNF) modifiers – precautions updated for the increased risk of lymphoma and other cancers in children and adolescents
- urea (Kerol AD) – monograph updated for new FDA-approved topical emulsion
- valganciclovir (Valcyte) – monograph updated for new FDA-approved oral solution and for CMV prophylaxis in pediatric patients older than 4 months
- valsartan (Diovan) – ADRs updated for post-marketing reports of vasculitis
- zoledronic acid (Reclast) – ADRs and contraindications updated for post-marketing reports of renal damage
- zolpidem (Edluar, Zolpimist) – monograph updated for FDA-approved sublingual tablet for insomnia and to avoid administration of the sublingual spray with or after a meal
IV COMPATIBILITY:
None at this time.
SPECIFIC CONTENT ISSUES: Selected content issues include, but are not limited to:
- New indication terms for anal cancer and biliary tract cancer added to select monographs
- The more specific indication terms of small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) were added to select monographs
- FDA MedWatch: Drug Safety Alerts and Label Changes
|
 |